To explore the smart supervision model for pharmaceuticals and enhance the efficiency of drug regulation， the Drug Administration of Xinjiang Uygur Autonomous Region （hereinafter referred to as "Xinjiang Administration"） has actively promoted the construction of the Digital and Intelligent Drug Supervision Integration Platform （hereinafter referred to as "Integration Platform"）. This initiative drives innovation in regulatory models and provides strong support for ensuring public drug safety. Based on the necessity of advancing smart supervision for pharmaceuticals and the policy background of Xinjiang Administration's construction of the Integration Platform， this study comprehensively introduces the objectives， construction approach， and overall architecture of the Integration Platform. It focuses on exploring the effectiveness of the practical application scenarios of Xinjiang Administration's Integration Platform. Leveraging the Integration Platform， Xinjiang Administration adopts the "Use New to Manage" approach， establishing a closed-loop process through intelligent approval and robotic inspection， unifying the entire Xinjiang under one network， and enhancing the precision and efficiency of regulation. It adopts the "Release New to Use" approach， strengthening convenience services， achieving full electronic administrative approval， and enhancing the convenience and satisfaction of businesses. Furthermore， it adopts the "Claim New to Handle" approach， promoting the full lifecycle traceability of "two products and one device". Relying on functions such as "Xinjiang Pharmacy" and "Legal Popularization + Online Science Popularization"， combined with digital reporting handling and risk early warning， it builds a social co-governance system and enhances the efficiency of government services. The Integration Platform has achieved remarkable results in synergistic efforts to promote "unifying the entire Xinjiang under one network， tracing the entire process with one code， and promoting development with one heart". It has realized cross-departmental and cross-business data interconnectivity， effectively enhancing the digitalization and intelligence level of drug regulation.